Positive data of uTREAT® in glioblastoma provides “green light” to proceed with next steps
The biodistribution results from Curasight A/S’ (“Curasight”) testing of uTREAT® for the treatment of glioblastoma are now available. The results are positive and provide “green light” to proceed to the next step.
As previously communicated, Curasight’s therapeutic technology uTREAT®, a uPAR-targeted radionuclide therapy, entered into preclinical testing in glioblastoma. The first step in testing new targeted radionuclides is the study of biodistribution, where both the binding to the implanted human glioblastoma tumors as well as distribution to organs are tested. The binding to the tumor needs to be sufficiently high to make a therapeutic response likely, and the biodistribution to organs needs to be such that severe side effects are unlikely. uTREAT® has now been tested in a human xenograft glioblastoma tumor model and passed both criteria, which is encouraging and constitutes a “green light” to proceed into further efficacy testing.
“The positive outcome of the biodistribution study is highly encouraging for our plan of making uTREAT® a therapy for glioblastoma patients. Considering that the uTREAT® technology previously was demonstrated to be effective and safe in both colorectal and prostate cancer, the positive biodistribution data came as no surprise. Nevertheless, I am most pleased that we cleared this first step in glioblastoma and now can proceed with the next step of testing,” says CEO Ulrich Krasilnikoff.
About high grade glioma and glioblastoma
Glioblastoma is the first indication for uTREAT®, but uTREAT® has also potential in several other cancer types expressing the biomarker uPAR. Almost all patients with glioblastoma express uPAR. A total of approx. 65.000 patients are diagnosed with primary brain tumors and more than 30.000 patients are diagnosed with the aggressive form, glioblastoma, annually in the US and EU. Approximately 10 % of the patients are children. The prognosis for individuals with glioblastoma is very poor as approximately 50 % of the patients die within 14 months and after five years from diagnosis only 5 % are still alive.
This information is such information that Curasight A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the care of the below contact person, for publication on 24 June, 2021.
For more information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.